Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence"

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2018 Jun 30

PMID 29956220

Citations 1

Authors

Bernard Silverman

Gary Bloomgren

Priya Jain

Kimberley Marcopul

Alexandra Silveira

James Fratantonio

Maria Sullivan

Sarah Akerman

Affiliations

Soon will be listed here.

Citing Articles

Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".

Dasgupta N, Saucier R, Wolfe D Drug Saf. 2018; 41(10):995-997.

PMID: 29956219 DOI: 10.1007/s40264-018-0692-9.

References

Krupitsky E, Nunes E, Ling W, Gastfriend D, Memisoglu A, Silverman B . Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013; 108(9):1628-37. DOI: 10.1111/add.12208. View

Tanum L, Solli K, Latif Z, Saltyte Benth J, Opheim A, Sharma-Haase K . Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017; 74(12):1197-1205. PMC: 6583381. DOI: 10.1001/jamapsychiatry.2017.3206. View

Morgan J, Schackman B, Leff J, Linas B, Walley A . Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2017; 85:90-96. PMC: 5750108. DOI: 10.1016/j.jsat.2017.07.001. View

Saxon A, Akerman S, Liu C, Sullivan M, Silverman B, Vocci F . Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction. 2018; 113(8):1477-1487. DOI: 10.1111/add.14199. View

Volkow N, Frieden T, Hyde P, Cha S . Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22):2063-6. DOI: 10.1056/NEJMp1402780. View

Saucier R, Wolfe D, Dasgupta N . Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. Drug Saf. 2018; 41(10):981-988. DOI: 10.1007/s40264-018-0653-3. View

Earley P, Zummo J, Memisoglu A, Silverman B, Gastfriend D . Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence. J Addict Med. 2017; 11(3):224-230. PMC: 5457834. DOI: 10.1097/ADM.0000000000000302. View

Krupitsky E, Nunes E, Ling W, Illeperuma A, Gastfriend D, Silverman B . Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377(9776):1506-13. DOI: 10.1016/S0140-6736(11)60358-9. View

Lott D . Extended-release naltrexone: good but not a panacea. Lancet. 2017; 391(10118):283-284. DOI: 10.1016/S0140-6736(17)32872-6. View

10.

Sirohi S, Kumar P, Yoburn B . Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J Pharmacol Exp Ther. 2007; 323(2):701-7. DOI: 10.1124/jpet.107.127019. View

11.

Lee J, Nunes Jr E, Novo P, Bachrach K, Bailey G, Bhatt S . Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017; 391(10118):309-318. PMC: 5806119. DOI: 10.1016/S0140-6736(17)32812-X. View

12.

Lee J, Friedmann P, Kinlock T, Nunes E, Boney T, Hoskinson Jr R . Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016; 374(13):1232-42. PMC: 5454800. DOI: 10.1056/NEJMoa1505409. View

13.

Arnold-Reed D, Hulse G, Hansson R, Murray S, ONeil G, Basso M . Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses. Addict Biol. 2003; 8(3):343-50. DOI: 10.1080/13556210310001602266. View

14.

Cornish J, Henson D, Levine S, Volpicelli J, Inturrisi C, Yoburn B . Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers. Am J Addict. 2018; 2(1):34-38. PMC: 6147145. View

15.

Kelty E, Hulse G . Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Policy. 2017; 46:54-60. DOI: 10.1016/j.drugpo.2017.05.039. View

16.

Volkow N . Medications for opioid use disorder: bridging the gap in care. Lancet. 2017; 391(10118):285-287. DOI: 10.1016/S0140-6736(17)32893-3. View

17.

Bardo M, Bhatnagar R, Gebhart G . Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat. Brain Res. 1983; 289(1-2):223-34. DOI: 10.1016/0006-8993(83)90023-9. View